Cardiff Oncology vs Rallybio
Rallybio is the larger business, with $858,000 of revenue in fiscal 2025 against $593,000 for Cardiff Oncology (1.4 times as much). Rallybio grew faster (34.9% against -13.2%). Rallybio kept more of each dollar of sales as profit: a net margin of -1046.4% against -7732.0%.
| Latest fiscal year | Cardiff OncologyCRDF, 2025 | RallybioRLYB, 2025 |
|---|---|---|
| Revenue | $593,000 | $858,000 |
| Revenue growth | -13.2% | 34.9% |
| Net income | −$45.9m | −$9.0m |
| Operating margin | — | -3853.6% |
| Net margin | -7732.0% | -1046.4% |
| Return on equity | -71.5% | -15.0% |
| Free cash flow | −$38.0m | −$29.8m |
| Cash | $17.5m | $31.4m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 31 | 14 |
| Market value | $58.6m | $85.2m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | — |
| Insider trades, 12 months | 4 buys, 0 sales | 14 buys, 2 sales |